IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Interferon-alfa (IFN-α) plays a significant role in the pathogenesis of several autoimmune rheumatic diseases.
• A persistent unmet medical need exists for effective treatments in systemic lupus erythematosus (SLE), primary Sjögren syndrome (pSS), systemic sclerosis (SSc), and dermatomyositis (DM).

Purpose of the Study:

• To review clinical and preclinical advancements in anti-IFN-α therapeutic strategies.
• To explore the potential of precision medicine in guiding anti-IFN-α treatment selection.

Main Methods:

• Review of current literature on anti-IFN-α treatments.
• Analysis of preclinical and clinical data for IFN-α targeted therapies.
• Examination of molecular profiling and data integration techniques.

Main Results:

• Direct neutralization of IFN-α has shown promising results.
• Targeting IFN-α production via cytosolic nucleic acid sensor pathways is effective.
• Blocking downstream effects through the type I IFN receptor demonstrates therapeutic potential.
• Molecular profiling aids in identifying patient subgroups likely to respond to therapy.

Conclusions:

• Anti-IFN-α therapies represent a promising avenue for treating autoimmune rheumatic diseases.
• Precision medicine approaches, utilizing molecular profiling, are crucial for optimizing patient selection and treatment outcomes.